Adult Onset Still Disease Clinical Trial
— MAOSDCOfficial title:
Multi-center Registration Study of Adult Onset Still's Disease in Chinese Population
This multi-center registration study will investigate the clinical characteristics of AOSD population in China , identify possible factors inducing the onset and active condition of AOSD in Chinese population , and identify the new high specific and sensitive markers of AOSD
Status | Recruiting |
Enrollment | 150 |
Est. completion date | December 31, 2022 |
Est. primary completion date | June 30, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - AOSD: Patients fulfill Japan's Yamaguch AOSD classification. - Control: Use 1:1 group matching, should meet the following condition -s : same gender as matching case; same age as matching case or the difference ranges within 1 year; no Immune related diseases (e.g. Psor -iasis, Systemic Lupus Erythematos -us, Dermatomyositis, Scleroderma, Rheumatoid Arthritis, Type 1 Diabet -es, Behcet's disease, Sjogren's Syndrome, Hyperthyroidism, etc.); no family history of immune related diseases. Exclusion Criteria: - Anyone with physical or mental illness that may affect the assessment will be excluded, such as patients with hearing or speech expression disorders. |
Country | Name | City | State |
---|---|---|---|
China | The Second Xiangya Hospital of Central South University | Hunan | Changsha |
Lead Sponsor | Collaborator |
---|---|
Second Xiangya Hospital of Central South University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | gene expression level and methylation level | The data of this study is managed by the Hunan Key Laboratory of Medical Epigenomics (Department of Dermatology, The Second Xiangya Hospital of Central South University). The authenticity, integrity and confidentiality of clinical data are required to be ensured, original case and case report form shall be filled out by investigator or the designated person of researcher and shall not be altered at will. If necessary, the name of the changer and the date of modification should be signed.
Statistical analysis will use GraphPad Prism or SPSS software. All statistical tests will be performed using a two-sided test, P values less than 0.05 will be considered statistically significant, the confidence interval uses 95%. The measurement data will be statistically described using mean ± standard deviation or median (minimum, maximum). Disease exposure factors and impact analysis will be based on descriptive statistical analysis. |
0 day |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04750863 -
Evaluation of Adult Onset Still Disease Classification Criteria and Differential Diagnosis at Eighteen Months of Follow-up
|
||
Completed |
NCT03311854 -
A Study to Investigate the Safety and Efficacy of Emapalumab, an Anti-IFN-gamma mAb in Patients With Systemic Juvenile Idiopathic Arthritis (sJIA) or Adult-onset Still's Disease (AOSD) Developing Macrophage Activation Syndrome/Secondary HLH (MAS/sHLH)
|
Phase 2 | |
Recruiting |
NCT04402086 -
Rheumatology Patient Registry and Biorepository
|